← Back to Search

Dietary Supplement

Whey protein alone for Sarcopenia

N/A
Waitlist Available
Led By Arny A Ferrando, Ph.D.
Research Sponsored by University of Arkansas
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* BMI between 20 and 30 kg/m\^2
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from 4.5 to 8.5 hours.
Awards & highlights
No Placebo-Only Group

Summary

Sarcopenia, a progressive loss of muscle mass, strength and function, is an inevitable natural process of aging. While it may be impossible to completely reverse the progress of sarcopenia, it is well established that intake of dietary protein through essential amino acids (EAAs) and whey protein increases anabolic response. The current study will test if a specially formulated mixture of EAAs and whey protein can maximally stimulate anabolic responses at the levels of whole body and muscle compared to whey protein alone.

Eligible Conditions
  • Sarcopenia

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from 4.5 to 8.5 hours.
This trial's timeline: 3 weeks for screening, Varies for treatment, and from 4.5 to 8.5 hours. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Protein Anabolism
Protein Synthesis

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups
Experimental Treatment
Group I: Whey protein aloneExperimental Treatment1 Intervention
Subjects will consume 12.6 g of whey protein isolate which is an equal amount to the double dose of EAAs/whey.
Group II: A single dose of EAAs/wheyExperimental Treatment1 Intervention
Subjects will consume 6.3 g of EAAs/whey in \~12 oz water.
Group III: A double dose of EAAs/wheyExperimental Treatment1 Intervention
Subjects will consume 12.6 g of EAAs/whey in \~12 oz water
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
6.3 g of EAAs mixture and whey protein isolate
2018
N/A
~20
12.6 g of whey protein isolate
2018
N/A
~20
12.6 g of EAAs mixture and whey protein isolate
2018
N/A
~20

Find a Location

Who is running the clinical trial?

University of ArkansasLead Sponsor
496 Previous Clinical Trials
150,648 Total Patients Enrolled
8 Trials studying Sarcopenia
202 Patients Enrolled for Sarcopenia
Arny A Ferrando, Ph.D.Principal InvestigatorUniversity of Arkansas
3 Previous Clinical Trials
34 Total Patients Enrolled
1 Trials studying Sarcopenia
19 Patients Enrolled for Sarcopenia
~2 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top